scholarly journals L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients

2019 ◽  
Vol Volume 11 ◽  
pp. 2579-2588 ◽  
Author(s):  
D Portal ◽  
L Hofstetter ◽  
I Eshed ◽  
C Dan Lantsman ◽  
T Sella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Surrogate Marker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skeletal Muscle Index ◽  
Lung Cancer Patients

scholarly journals Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients

2015 ◽  
Vol 9 ◽  
pp. CMO.S30891 ◽  
Author(s):  
Syed Hasan Raza Jafri ◽  
Carlos Previgliano ◽  
Keerti Khandelwal ◽  
Runhua Shi
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Stage Ii ◽  
Small Cell Lung ◽  
Skeletal Muscle Index

Introduction Cancer cachexia affects many advanced non-small-cell lung cancer (NSCLC) patients. Cachexia index (CXI) was developed to assess the degree of cachexia in these patients. Methods Patients with metastatic NSCLC diagnosed between January 1, 2000, and June 30, 2011, at our institution were retrospectively studied. Abdominal computed tomography scans done within 1 month of diagnosis were reviewed to estimate skeletal muscle area (SMA) and skeletal muscle index (SMI) at the L3 level. CXI was developed as follows: [Formula: see text] where SMI is the skeletal muscle index, Alb is the serum albumin, and NLR is the NLR neutrophil-to-lymphocyte ratio. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Survival among various factors was calculated using the log-rank test. Multivariate Cox regression was used to perform survival analysis in order to estimate the effects of various factors. Results Patients were divided into two groups around the median into stage I cachexia (CXI ≥35, n = 56) and stage II cachexia (CXI <35, n = 56). Groups did not differ in age, gender, ethnicity, or histology of cancer. Patients with stage II cachexia had significantly worse PFS (2.45 vs 5.43 months, P < 0.0001) and OS (3.45 vs 8.8 months, P = 0.0001) than those with stage I cachexia. On multivariate analysis adjusting for gender, race, and histology, patients with stage II cachexia were found to have worse PFS (hazard ratio [HR] 1.94, 95% confidence interval [CI] 1.27–2.95) and OS (HR 1.53, 95% CI 1.0009–2.34). Conclusion The CXI is a novel index for estimating cachexia that also correlates with prognosis in both men and women with advanced NSCLC.

scholarly journals Skeletal Muscle Depletion Is Associated with Reduced Plasma (n-3) Fatty Acids in Non-Small Cell Lung Cancer Patients

2010 ◽  
Vol 140 (9) ◽  
pp. 1602-1606 ◽  
Author(s):  
Rachel A. Murphy ◽  
Marina Mourtzakis ◽  
Quincy S. Chu ◽  
Tony Reiman ◽  
Vera C. Mazurak
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Fatty Acids ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document